JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Other Events

Item 8.01 Other Events.

On April28, 2017, Jaguar Animal Health,Inc. (Jaguar) issued a
press release announcing its entry into an exclusive distribution
agreement with JP Equine Services for distribution of Jaguars
lead non-prescription products, Neonorm Foal and Neonorm Calf in
Japan. The press release also contained information regarding the
determination by the NASDAQ Hearing Panel to grant Jaguars
request for continued listing on NASDAQ, subject to completion of
Jaguars proposed merger with Napo Pharmaceuticals,Inc. on or
before July31, 2017 and Jaguars compliance with NASDAQs $2.5
million stockholders equity requirement as a result of the
merger.

A copy of the press release is attached hereto as Exhibit99.1 and
incorporated by reference herein.

Disclaimer on Forward-looking Statements

This Current Report on Form8-K, including the press release,
contains forward-looking statements within the meaning of section
27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. These include statements
regarding the completion of Jaguars proposed merger with Napo
Pharmaceuticals,Inc. on or before July31, 2017, Jaguars ability
to timely evidence compliance with the terms of the Panels
decision, Jaguars intention to develop species-specific
formulations of Neonorm in additional target species, and Jaguars
plan to develop formulations of Canalevia for cats, horses and
dogs. In some cases, you can identify forward-looking statements
by terms such as may, will, should, expect, plan, aim,
anticipate, could, intend, target, project, contemplate, believe,
estimate, predict, potential or continue or the negative of these
terms or other similar expressions. The forward-looking
statements in this release are only predictions. Jaguar has based
these forward-looking statements largely on its current
expectations and projections about future events. These
forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguars control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise
any forward-looking statements contained herein, whether as a
result of any new information, future events, changed
circumstances or otherwise.

Item9.01 Financial Statements and
Exhibits

(d)Exhibits

About JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX)

Jaguar Animal Health, Inc. is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products to address needs in animal health. As of December 31, 2016, its pipeline includes prescription drug product candidates for nine indications across multiple species, and non-prescription products targeting seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Equilevia, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm.

JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) Recent Trading Information

JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) closed its last trading session down -0.040 at 0.820 with 68,952 shares trading hands.